Extraordinary meeting of the Committee for Medicinal Products for Human Use (CHMP): 4 October 2021
Location: Virtual meeting
This extraordinary meeting is organised in the context of the evaluation of an application for the use of:
- additional and booster doses for the COVID-19 vaccine Comirnaty;
- additional doses for the COVID-19 vaccine Spikevax.
The aim of the meeting is to conclude these evaluations, if possible.
This extraordinary meeting takes place within the monthly meeting of the Committee for Medicinal Products for Human Use (CHMP) for preparatory and organisational matters.
The CHMP is the committee that is responsible for preparing the Agency's opinions on all questions concerning human medicines.